CFB and cancer: The efficacy of BJ-1113 (at 10 μM) at suppressing 5-HT-induced cancer cell invasion was similar to that achieved by co-treating DDA (100 μM) and gallein (10 μM), which hints that BJ-1113 may target the autocrine action of 5-HT by inhibiting Gα and Gβγ signaling.